Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Interferon response in clinical samples (IRIS)

A technology for interferon beta and biological samples, which is applied in the direction of material testing products, microbial determination/inspection, biochemical equipment and methods, etc., and can solve problems such as no cure.

Inactive Publication Date: 2011-09-21
BAYER HEALTHCARE LLC
View PDF94 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No single lab test is currently available to prove or rule out MS, and there is no cure
Additionally, no laboratory tests exist to identify treatment-responsive and non-responsive patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon response in clinical samples (IRIS)
  • Interferon response in clinical samples (IRIS)
  • Interferon response in clinical samples (IRIS)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0125] Example 1: IRIS gene expression analysis

[0126] Relative gene expression is measured with a sequence detection system (eg ABI Prism 7900HT) using application software (eg SDS2.1) designed for the detection unit. Using Equation 2- δδCTThe expression level of each IRIS gene was calculated by the comparative CT method, where δδCT equals the normalized signal level in sample "A" (eg, IFNβ-stimulated) relative to the normalized signal level in a calibration sample (eg, non-stimulated control). Samples can be normalized using the GAPDH or HPRT1 housekeeping genes. Alternatively, when examining responses in patient PBMC samples, T cells (CD3), B cells (CD19), monocytes (CD14), dendritic cells (ITGAX), neutrophils (NCAM), or NK cells can be used Samples were normalized for cell lineage markers of cells (CD16). For Nab analysis, IRIS gene expression was compared between samples containing patient serum concentrations with 10 LU / mL IFNβ and calibration samples with only 10 L...

Embodiment 2

[0127] Example 2: Nab Assay Patient Data

[0128] Using the IRIS gene expression analysis described above, we found that the degree of neutralization of IFNβ induction appears to be unique for each IRIS gene analyzed. For example, the standard IFNβ-responsive gene MxA gene is very sensitive to neutralization, whereas other IRIS genes require higher serum neutralization concentrations. (see Figure 6 ). This was shown in an analysis of patient sera previously characterized by viral inhibition assays as having potent Nab activity. Furthermore, sensitivity to neutralization (as indicated by a gene's TRU titer) did not correlate with the magnitude of the response for that particular gene. (see Figure 7 ).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a specific set of genes useful for determining the efficacy of a treatment against multiple sclerosis (MS). Further, the invention provides an array of these genes useful for evaluating efficacy of a MS treatment. Also provided are methods for evaluating efficacy of an MS treatment and a method for detecting neutralizing antibodies in patient response to interferonss-1B treatment of MS.

Description

[0001] Mention related applications [0002] This application claims priority to US Provisional Application Serial No. 61 / 097,227, filed September 16, 2008, which is hereby incorporated by reference in its entirety. field of invention [0003] The present invention relates to a specific set of genes that can be used to determine the efficacy of treatments against multiple sclerosis (MS). [0004] Mention the sequence listing [0005] This application incorporates by reference the accompanying Sequence Listing both on paper and in electronic copy in .txt format created September 12, 2008. Applicant further warrants that the contents contained in the paper and electronic copies are the same. Background of the invention [0006] Many disease states are characterized by differences in the expression levels of various genes, either through changes in the copy number of inherited DNA or through changes in the transcriptional levels of specific genes (e.g., through control of ini...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q2600/112C12Q2600/158C12Q1/6883C12Q2600/136G01N33/48
Inventor 爱德华·克罗兹佩德罗·帕兹沙林·维利奇科山口健T·C·瓦格纳
Owner BAYER HEALTHCARE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com